İntrahepatik kolanjiyosellüler karsinomlarda transarteriyel radyoembolizasyon tedavisinin sağkalım üzerine etkisi

Amaç: Bu çalışmanın amacı, cerrahi tedaviye uygun olmayan ve transarteriyel radyoembolizasyon yöntemi ile tedavi edilen intrahepatik kolanjiyosellüler karsinom hastalarının sağkalım sonuçlarını sunmaktır.Gereç ve Yöntem: Bu çalışmaya intrahepatik kolanjiyosellüler karsinom tanısı almış ve cerrahi tedaviye uygun olmayan 28 hasta dahil edildi. Hastaların tamamı transarteriyel radyoembolizasyon yöntemi ile tedavi edildi. Tanı konduktan sonra takipleri başlayan hastaların sağkalım süreleri kayıt altına alındı. Sağkalım süreleri hesaplanırken Kaplan-Meier yaşam analizi kullanıldı.Bulgular: Çalışmada toplamda 28 hasta değerlendirilmiştir. Ortalama yaş 60,46 yıl olup minimum yaş 36 yıl, maksimum yaş ise 84 yıldır. Hastaların medyan takip süresi 14 ay olarak hesaplandı (min:3– maks:33). Hastaların medyan sağkalım süresi 22 (min:3 ay, max:33 ay) aydır. Ayrıca kemoterapi almış hastalar ile almamış hastalar, soliter tümörü olan hastalar ile multifokal tümörü olan hastalar, tümörü unilobar olan hastalar ile bilobar olan hastaların sağkalım süreleri hesaplandı ve gruplar arasında anlamlı bir farklılık bulunmadı.Sonuç: Modern kemoterapi uygulamaları bu sağkalım oranında artış sağlamış olsa da medyan sağkalımı 12 ayın üzerine çıkaramamıştır. Bu veriler dikkate alındığında transarteriyel radyoembolizasyon tedavisinin sağkalım süresini uzattığı görülmektedir.

Effect of transarterial radioembolization therapy on survival in intrahepatic cholangiocellular carcinoma

Purpose: The aim of this study was to present the survival analyses of patients with intrahepatic cholangiocellular carcinoma who are ineligible forsurgical treatment and treated with transarterial radioembolization.Materials and Methods: Twenty-eight patients with intrahepatic cholangiocellular carcinoma who were not eligible for surgical treatment were included in this study. All patients were treated by transarterial radioembolization. The survival time of the patients who were followed up after diagnosis was recorded. Kaplan-Meier survival analysis was used to calculate survival.Results: The mean age was 60.46 years. While minimum age of patients was 36 years, maximum age of patients 84 years. The median follow-up was 14 months (min:3, max:33). The median survival time of the patients was 22 months (min:3 months, max:33 months). In addition, the survival time of patients who received chemotherapy and patients who did not receive chemotherapy, patients with solitary tumor, patients with multifocal tumor, patients with tumor unilobar and patients with bilobar were calculated and no significant difference was found between the groups.Conclusion: Although modern chemotherapy has increased this survival rate, it has not been able to increase the median survival beyond 12 months. When these data are taken into consideration, it is seen that transarterial radioembolization treatment prolongs survival.

___

  • 1. Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy and safety study. Cardiovasc Intervent Radiol. 2013;36:440-8.
  • 2. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115– 25.
  • 3. Park J, Kim M-H, Kim K-P, Park DH, Moon S-H, Song TJ et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy or radiotherapy: a large-scale observational study. Gut Liver. 2009;3:298–305.
  • 4. Seidensticker R, Ricke J, Seidensticker M. Integration of chemoembolization and radioembolization into multimodal treatment of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29:319-32.
  • 5. Khan SA, Thomas HC, Davidson BR, TaylorRobinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14.
  • 6. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95-111
  • 7. Akinwande O, Shah V, Mills A, Noda C, Weiner E, Foltz G et al. Chemoembolization versus Radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity. Hepat. Oncol.2017;4:75–81.
  • 8. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.
  • 9. Bourien H, Palard X, Rolland Y, Le Du F, Beuzit L, Uguen T et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging. 2019;146:669-676
  • 10. Nezami N, Kokabi N, Camacho JC, Schuster DM, Xing M, Kim HS. Y90 radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. Nucl Med Biol. 2018;59:22-8.
  • 11. Fidelman N, Kerlan RK, Hawkins RA. 90Y Glass Microspheres for the Treatment of Unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Canc. 2014;45:168–80.
  • 12. Zechlinski JJ, Rilling WS. Transarterial therapies for the treatment of intrahepatic cholangiocarcinoma. Semin Intervent Radiol. 2013;30:21–7.
  • 13. Hoffmann RT, Paprottka PM, Schön A, Bamberg F, Haug A, Dürr EM et al. Transarterial hepatic yttrium90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35:105-16.
  • 14. Jakobs TF, Hoffmann RT, Fischer, Stemmler HJ, Tatsch K, La Fougere C T et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19:683–90.
  • 15. Peterson JL, Vallow LA, Johnson DW, Heckman MG, Diehl NN, Smith AA et al. Complication safter 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients. Brachytherapy. 2013;12:573–9.
  • 16. Ibrahim SM, Mulcahy MF, Lewandowski RJ. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113:2119–28.
  • 17. Gangi A, Shah J, Hatfield N. Intrahepatic cholangiocarcinoma treated with transarterial yttrium90 glass microsphere radioembolization: results of a single institution retrospective study. J Vasc Interv Radiol. 2018;9:1101-08.
  • 18. Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17:484-91.
  • 19. Soydal Ç, Kucuk NO, Bilgic S, Ibis E. Radioembolization with 90Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors. Ann Nucl Med. 2016;30:29–34.
  • 20. Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015;41:120-7.
  • 21. Hickey R, Mulcahy MF, Lewandowski RJ, Totianna Prudhomme CNP, Eduardo Ehrenwald MD, Brian Baigorri et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys. 2014;88:1025-31.
  • 22. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28-37.
  • 23. Mahnken AH. Current status of transarterial radioembolization. World J Radiol. 2016;28:8:449-59.
  • 24. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013;57:1078–87.
Cukurova Medical Journal-Cover
  • ISSN: 2602-3032
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1976
  • Yayıncı: Çukurova Üniversitesi Tıp Fakültesi